Association between the type and length of tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis

Journal of Drugs in Dermatology

Volumn 12, Issue 8, 2013, Pages 899-903

  Wu, Jashin J ^a   Poon, Kwun Yee T ^b   Bebchuk, Judith D ^b  

^a KAISER PERMANENTE MEDICAL CENTER   (United States)

^b Kaiser Permanente Southern California ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CYCLOSPORIN; ETANERCEPT; ETRETIN; HYDROXYUREA; INFLIXIMAB; ISOTRETINOIN; MERCAPTOPURINE; METHOTREXATE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; TUMOR NECROSIS FACTOR INHIBITOR; USTEKINUMAB;

AGED; ARTICLE; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; COHORT ANALYSIS; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PHOTOTHERAPY; PRESCRIPTION; PROPORTIONAL HAZARDS MODEL; PSORIASIS; PSORIATIC ARTHRITIS; PUVA; RETROSPECTIVE STUDY; SYSTEMIC THERAPY; ULTRAVIOLET B RADIATION;

ADMINISTRATION, CUTANEOUS; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; COHORT STUDIES; DERMATOLOGIC AGENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PHOTOTHERAPY; PROPORTIONAL HAZARDS MODELS; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; RISK; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84882301818     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Hinchman KF, Liao W, Koo J, Wu JJ. Current and potential applications of pharmacogenetics in the treatment of psoriasis. In: Koo JY, Lebwohl MG, Lee CS, Weinstein GD and Gottlieb A editors. Moderate-To-Severe Psoriasis. New York, NY: Informa Healthcare USA Inc; 2009. p 379-92.
2. Channual J, Wu JJ, Dann FJ. Effects of TNF-alpha blockade on metabolic syndrome in psoriasis: lessons learned from rheumatoid arthritis and psoriatic arthritis. Dermatol Ther. 2009;22:61-73.
3. El-Mongy S, Fathy H, Abdelaziz A, Omran E, George S, Neseem N et al. Subclinical atherosclerosis in patients with chronic psoriasis: a potential association. J Eur Acad Dermatol Venereol. 2010 24:661-6.
4. Shapiro J, Cohen AD, David M, Hodak E, Chodik G, Viner A et al. The association between psoriasis, diabetes mellitus, and atherosclerosis in Israel: a case-control study. J Am Acad Dermatol. 2007 56:629-34.
5. Kimball AB, Robinson D Jr, Wu Y, Guzzo C, Yeilding N, Paramore C et al. Cardiovascular disease and risk factors among psoriasis patients in two US healthcare databases, 2001-2002. Dermatology. 2008;217:27-37.
6. Qureshi AA, Choi HK, Setty AR, Curhan GC. Psoriasis and the risk of diabetes and hypertension: a prospective study of US female nurses. Arch Dermatol. 2009;145:379-82.
7. Prodanovich S, Kirsner RS, Kravetz JD, Ma F, Martinez L, Federman DG. Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality. Arch Dermatol. 2009 145:700-3.
8. Koebnick C, Black MH, Smith N, Der-Sarkissian JK, Porter AH, Jacobsen SJ et al. The association of psoriasis and elevated blood lipids in overweight and obese children. J Pediatr. 2011;159:577-83.
9. Kaye JA, Li L, Jick SS. Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. Br J Dermatol. 2008;159:895-902.
10. Herron MD, Hinckley M, Hoffman MS, Papenfuss J, Hansen CB, Callis KP et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol. 2005;141:1527-34.
11. Love TJ, Qureshi AA, Karlson EW, Gelfand JM, Choi HK. Prevalence of the metabolic syndrome in psoriasis: results from the National Health and Nutrition Examination Survey, 2003-2006. Arch Dermatol. 2011 147:419-24.
12. Ludwig RJ, Herzog C, Rostock A, Ochsendorf FR, Zollner TM, Thaci D et al. Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol. 2007;156:271-6.
13. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296:1735-41.
14. Gelfand JM, Dommasch ED, Shin DB, Azfar RS, Kurd SK, Wang X et al. The risk of stroke in patients with psoriasis. J Invest Dermatol. 2009 129:2411-8.
15. Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J. 2010 31:1000-6.
16. Abuabara K, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Causespecific mortality in patients with severe psoriasis: a population-based cohort study in the U.K. Br J Dermatol. 2010 163:586-92.
17. Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003;349:2014-22.
18. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet. 2001;357:1842-7.
19. Menter A, Tyring SK, Gordon K, Kimball AB, Leonardi CL, Langley RG et al. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol. 2008;58:106-15.
20. Kavanaugh A, McInnes I, Mease P, Krueger GG, Gladman D, Gomez-Reino J et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum. 2009 60:976-86.
21. Wu JJ, Poon KT, Channual JC, Shen AY. Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis. Arch Dermatol. Published online August 20, 2012.
22. Saurat JH, Stingl G, Dubertret L, Papp K, Langley RG, Ortonne JP et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol. 2008 158:558-66.
23. Reich K, Nestle FO, Papp K, Ortonne JP, Evans R, Guzzo C et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet. 2005 366:1367-74.
24. Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet. 2006 367:29-35.
25. Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L et al. Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study. Ann Rheum Dis. 2010 69:817-21.
26. Jamnitski A, Bartelds GM, Nurmohamed MT, van Schouwenburg PA, van Schaardenburg D, Stapel SO et al. The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept. Ann Rheum Dis. 2011 70:284-8.
27. Lecluse LL, Driessen RJ, Spuls PI, de Jong EM, Stapel SO, van Doorn MB et al. Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis. Arch Dermatol. 2010 146:127-32.
28. Radstake TR, Svenson M, Eijsbouts AM, van den Hoogen FH, Enevold C, van Riel PL et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis. 2009 68:1739-45.
29. Dore RK, Mathews S, Schechtman J, Surbeck W, Mandel D, Patel A et al. The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis. Clin Exp Rheumatol. 25:40-6.
30. Gordon K, Papp K, Poulin Y, Gu Y, Rozzo S, Sasso EH. Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL. J Am Acad Dermatol. 2012;66 241-51.
31. Papp KA, Poulin Y, Bissonnette R BM, Toth D, Rosoph L, Poulin-Costello M et al. Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population. J Am Acad Dermatol. 2012;66:e33-45.
32. Papoutsaki M, Talamonti M, Giunta A, Costanzo A, Ruzzetti M, Teoli M et al. The impact of methodological approaches for presenting long-term clinical data on estimates of efficacy in psoriasis illustrated by three-year treatment data on infliximab. Dermatology. 2010;221:43-7.
33. Ryan C, Leonardi CL, Krueger JG, Kimball AB, Strober BE, Gordon KB et al. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA. 2011 306:864-71.
34. Tzellos T, Kyrgidis A, Zouboulis CC. Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials. J Eur Acad Dermatol Venereol. 2012 [Epub ahead of print].
35. Papp KA, Leonardi C, Menter A, Ortonne JP, Krueger JG, Kricorian G et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med. 2012 366:1181-9.
36. Leonardi C, Matheson R, Zachariae C, Cameron G, Li L, Edson-Heredia E et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med. 2012 366:1190-9.
37. Wu JJ. Anti-interleukin-17 monoclonal antibody ixekizumab in psoriasis. N Engl J Med. 2012 367:274-5.